Novocure’s Second Generation Optune System for Glioblastoma Now FDA Approved
Novocure, a company now headquartered on the Jersey Isle, has announced FDA approval of the second generation of its groundbreaking Optune system. The Optune delivers so-called Tumor Treating Fields (TTFields) that interfere with cell division, in a sense pausing the development of tumors that are otherwise extremely difficult to treat. When cells divide they create mitotic spindles, tiny strings that pull on chromosomes to pry them apart for duplication. These spindles are susceptible to electric fields due to a natural charge, so finely tuning the field can prevent their activity and, if accurately directed, stop tumors from growing.…
Read More